Table 2.
Characteristics of OSCC patients in relation to cumulative survival.
| Variables | No. of patients (%) | OS (%) | P† | |
|---|---|---|---|---|
| Age | ≥ 71.3 | 103 (50.2) | 56.9 | 0.006** |
| (years) | < 71.3 | 102 (49.8) | 72.8 | |
| Gender | Male | 123 (60.0) | 68.6 | 0.501 |
| Female | 82 (40.0) | 60.2 | ||
| Tabaco consumption | Present | 27 (13.2) | 48.9 | 0.444 |
| Pre | 31 (15.1) | 77.2 | ||
| Never | 147 (71.7) | 66.8 | ||
| Alcohol consumption | Present | 65 (31.7) | 69.9 | 0.348 |
| None | 140 (68.3) | 62.3 | ||
| Primary site | Tongue | 76 (37.1) | 79.9 | 0.069 |
| Lower gingiva | 65 (31.7) | 55.9 | ||
| Buccal mucosa | 22 (10.7) | 62.2 | ||
| Upper gingiva | 19 (9.3) | 61.5 | ||
| Floor of the mouth | 13 (6.3) | 39.5 | ||
| Others | 10 (4.9) | 60.0 | ||
| Stage | I | 38 (18.5) | 88.0 | < 0.001** |
| II | 52 (25.4) | 71.5 | ||
| III | 28 (13.7) | 77.4 | ||
| IV A | 73 (35.6) | 49.4 | ||
| IV B | 13 (6.3) | 44.9 | ||
| IV C | 1 (0.5) | 0 | ||
| T classification | T1 | 40 (19.5) | 89.0 | < 0.001** |
| T2 | 62 (30.2) | 67.1 | ||
| T3 | 35 (17.1) | 76.0 | ||
| T4a | 56 (27.3) | 43.8 | ||
| T4b | 12 (5.9) | 40.0 | ||
| N classification | N0 | 132 (64.4) | 71.5 | 0.002** |
| N1 | 25 (12.2) | 62.3 | ||
| N2a | 1 (0.5) | 0 | ||
| N2b | 35 (17.1) | 56.8 | ||
| N2c | 10 (4.9) | 19.0 | ||
| N3b | 2 (1.0) | 50.0 | ||
| M classification | M0 | 204 (99.5) | 65.3 | < 0.001** |
| M1 | 1 (0.5) | 0 | ||
| Histological grade | Well | 105 (51.2) | 73.7 | 0.106 |
| Moderate | 80 (39.0) | 59.7 | ||
| Poor | 11 (5.4) | 25.5 | ||
| Others | 9 (4.4) | 66.7 | ||
| NLR | ≥ 3.59 | 51 (24.9) | 50.4 | < 0.001** |
| < 3.59 | 154 (75.1) | 70.0 | ||
| SIRI | ≥ 1.19 | 59 (28.8) | 47.7 | 0.001** |
| < 1.19 | 146 (71.2) | 71.7 | ||
| SII | ≥ 823.1 | 51 (24.9) | 50.1 | < 0.001** |
| < 823.1 | 154 (75.1) | 70.3 | ||
| LMR | ≥ 5.0 | 95 (46.3) | 75.2 | < 0.001** |
| < 5.0 | 110 (53.7) | 56.1 | ||
| CAR | ≥ 0.032 | 71 (34.6) | 35.0 | < 0.001** |
| < 0.032 | 134 (65.4) | 79.1 | ||
| CRP | ≥ 0.105 | 80 (39.0) | 40.6 | < 0.001** |
| (mg/dL) | < 0.105 | 125 (61.0) | 78.3 | |
| Alb | ≥ 4.15 | 114 (55.6) | 76.0 | < 0.001** |
| (g/dL) | < 4.15 | 91 (44.4) | 51.5 | |
| Management | Surgery | 116 (56.6) | 92.1 | < 0.001** |
| Surgery + radiotherapy or chemoradiotherapy | 51 (24.9) | 51.3 | ||
| Radiotherapy | 38 (18.5) | 15.5 | ||
| Local recurrence | Present | 39 (19.0) | 10.0 | < 0.001** |
| None | 166 (81.0) | 79.5 | ||
| Neck recurrence | Present | 15 (7.3) | 6.7 | < 0.001** |
| None | 190 (92.7) | 71.3 | ||
| Distant metastasis | Present | 20 (9.8) | 14.3 | < 0.001** |
| None | 185 (90.2) | 70.8 |
†By log-rank test.
*P < 0.05 Statistically significant difference, **P < 0.01 Statistically significant difference.
OS, overall survival; NLR, neutrophil/lymphocyte ratio; SIRI, systemic inflammation response index; LMR, lymphocyte/monocyte ratio; SII, systemic immune-inflammation index; CAR, C-reactive protein albumin/albumin ratio.